Identification
- Name
- Mirabegron
- Accession Number
- DB08893
- Description
Mirabegron is a beta-3 adrenergic receptor agonist for the management of overactive bladder. It is an alternative to antimuscarinic drugs for this indication. FDA approved on June 28, 2012.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Mirabegron (DB08893)
- Weight
- Average: 396.506
Monoisotopic: 396.161996722 - Chemical Formula
- C21H24N4O2S
- Synonyms
- Mirabegron
- External IDs
- YM-178
- YM178
Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:Accelerate your drug discovery research with our fully connected ADMET dataset- Indication
Mirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
- Associated Conditions
- Contraindications & Blackbox Warnings
Contraindications & Blackbox WarningsWith our commercial data, access important information on dangerous risks, contraindications, and adverse effects.Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects- Pharmacodynamics
Mirabegron has little effect on the mean maximum flow rate or mean detrusor pressure at maximum flow rate in patients with lower urinary tract symptoms and bladder outlet obstruction. Furthermore, mirabegron increases blood pressure in a dose dependent manner. However, this effect is reversible when mirabegron is discontinued. Mirabegron also increases heart rate in a dose dependent manner. The dose in which half-maximal efficacy is demonstrated is 25 mg. Comparatively, the dose in which maximal efficacy is demonstrated is 100 mg.
- Mechanism of action
Mirabegron is a potent and selective agonist for beta-3 adrenergic receptors. Once beta-3 receptors are activated, the detrusor smooth muscle relaxes to allow for a larger bladder capacity. At higher doses (200 mg), there is a potential for mirabegron to activate beta-1 and beta-2 adrenergic receptors.
Target Actions Organism ABeta-3 adrenergic receptor agonistHumans - Absorption
The absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increase more than dose proportionally. This relationship is more apparent at doses above 50 mg. Females generally have a lower magnitude of increase of Cmax and AUCtau compared to males when doses of mirabegron doubles or quadruples. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose. Tmax, oral dose, healthy subjects= 3.5 hours;
- Volume of distribution
Vd, steady state, IV dose = 1670 L. This high value suggests that mirabegron is extensively distributed in the body.
- Protein binding
71% bound to plasma proteins. It binds to albumin and alpha-1-acid glycoprotein with moderate affinity.
- Metabolism
Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. The major circulating entity is mirabegron. Two major and inactive metabolites (phase 2 glucuronides) are produced. Although mirabegron is a substrate for CYP2D6 and CYP3A4, its role in the elimination of the drug is limited. Studies also suggest that CYP3A4 is the main enzyme that facilitates the oxidative metabolism of the drug. Furthermore, butylcholinesterase, uridine diphospho-glucuronosyltransferases (UGT), and possibly alcohol dehydrogenase may be involved with the metabolism of mirabegron.
- Route of elimination
Mirabegron is eliminated via urine (radiolabeled drug: 55%; unchanged drug: ~25%) and feces (radiolabeled drug: 34%; unchanged drug: 0%). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Extent of elimination via urine is dose-dependent.
- Half-life
Terminal elimination half-life = 50 hours
- Clearance
Total body clearance (CLtot), IV dose = 57 L/h; Renal clearance (CLR) = 13 L/h
- Adverse Effects
Reduce medical errorsand improve treatment outcomes with our comprehensive & structured data on drug adverse effects.Reduce medical errors & improve treatment outcomes with our adverse effects data- Toxicity
Most commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAbacavir Abacavir may decrease the excretion rate of Mirabegron which could result in a higher serum level. Abametapir The serum concentration of Mirabegron can be increased when it is combined with Abametapir. Abatacept The metabolism of Mirabegron can be increased when combined with Abatacept. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Mirabegron. Abiraterone The metabolism of Mirabegron can be decreased when combined with Abiraterone. Acebutolol The metabolism of Mirabegron can be decreased when combined with Acebutolol. Aceclofenac Aceclofenac may decrease the excretion rate of Mirabegron which could result in a higher serum level. Acemetacin Acemetacin may decrease the excretion rate of Mirabegron which could result in a higher serum level. Acetaminophen The metabolism of Mirabegron can be decreased when combined with Acetaminophen. Acetazolamide Acetazolamide may increase the excretion rate of Mirabegron which could result in a lower serum level and potentially a reduction in efficacy. 
Improve patient outcomesBuild effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.Learn more - Food Interactions
- Take with or without food. Food decreases drug absorption, but not to a clinically significant extent.
Products
Comprehensive & structured drug product infoFrom application numbers to product codes, connect different identifiers through our commercial datasets.Easily connect various identifiers back to our datasets- Product Images
- International/Other Brands
- Betanis / Metmiga
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Betmiga Tablet, extended release 50 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU 
Betmiga Tablet, extended release 50 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 50 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 25 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 25 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 25 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 50 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 50 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 25 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU Betmiga Tablet, extended release 50 mg Oral Astellas Pharma Europe Bv 2016-09-08 Not applicable EU
Categories
- ATC Codes
- G04BD12 — Mirabegron
- Drug Categories
- Adrenergic Agents
- Adrenergic Agonists
- Adrenergic beta-3 Receptor Agonists
- Adrenergic beta-Agonists
- Agents producing tachycardia
- Agents that produce hypertension
- Amides
- Amines
- Anilides
- Aniline Compounds
- Cholinesterase substrates
- Cytochrome P-450 CYP2D6 Inhibitors
- Cytochrome P-450 CYP2D6 Inhibitors (moderate)
- Cytochrome P-450 CYP2D6 Substrates
- Cytochrome P-450 CYP3A Substrates
- Cytochrome P-450 CYP3A4 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Substrates
- Drugs for Urinary Frequency and Incontinence
- Drugs that are Mainly Renally Excreted
- Genito Urinary System and Sex Hormones
- Neurotransmitter Agents
- P-glycoprotein inhibitors
- P-glycoprotein substrates
- Potential QTc-Prolonging Agents
- QTc Prolonging Agents
- Selective Beta 3-adrenergic Agonists
- Sulfur Compounds
- Urological Agents
- Urologicals
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Anilides
- Direct Parent
- Anilides
- Alternative Parents
- Phenethylamines / N-arylamides / 2,4-disubstituted thiazoles / Aralkylamines / 2-amino-1,3-thiazoles / Heteroaromatic compounds / 1,2-aminoalcohols / Amino acids and derivatives / Secondary alcohols / Secondary carboxylic acid amides show 8 more
- Substituents
- 1,2-aminoalcohol / 1,3-thiazol-2-amine / 2,4-disubstituted 1,3-thiazole / Alcohol / Amine / Amino acid or derivatives / Anilide / Aralkylamine / Aromatic alcohol / Aromatic heteromonocyclic compound show 22 more
- Molecular Framework
- Aromatic heteromonocyclic compounds
- External Descriptors
- monocarboxylic acid amide, 1,3-thiazole, aromatic amide, ethanolamines (CHEBI:65349)
Chemical Identifiers
- UNII
- MVR3JL3B2V
- CAS number
- 223673-61-8
- InChI Key
- PBAPPPCECJKMCM-IBGZPJMESA-N
- InChI
- InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
- IUPAC Name
- 2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
- SMILES
- NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1
References
- General References
- Takasu T, Ukai M, Sato S, Matsui T, Nagase I, Maruyama T, Sasamata M, Miyata K, Uchida H, Yamaguchi O: Effect of (R)-2-(2-aminothiazol-4-yl)-4'-{2-[(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther. 2007 May;321(2):642-7. Epub 2007 Feb 9. [PubMed:17293563]
- Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899]
- External Links
- KEGG Drug
- D09535
- PubChem Compound
- 9865528
- PubChem Substance
- 175427137
- ChemSpider
- 8041219
- 1300786
- ChEBI
- 65349
- ChEMBL
- CHEMBL2095212
- ZINC
- ZINC000001996784
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Mirabegron
- AHFS Codes
- 86:12.08.12 — Selective Beta 3-adrenergic Agonists
- FDA label
- Download (510 KB)
- MSDS
- Download (481 KB)
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Not Available Healthy Volunteers / Pharmacokinetics of Mirabegron and Tolterodine 1 4 Completed Basic Science Food Effect / Healthy Chinese Subjects / Pharmacokinetics of Mirabegron 1 4 Completed Treatment Benign Prostatic Hyperplasia (BPH) / Urinary Bladder, Overactive 1 4 Completed Treatment Disseminated Sclerosis 1 4 Completed Treatment Impaired Cognition / Parkinson's Disease (PD) / Urinary Bladder, Overactive 1 4 Completed Treatment Parkinson's Disease (PD) 1 4 Completed Treatment Urinary Bladder, Overactive 8 4 Completed Treatment Urinary Incontinence, Urge 1 4 Recruiting Prevention Dementia / Lower Urinary Tract Symptoms (LUTS) / Urinary Bladder, Overactive / Urinary Incontinence, Urge 1 4 Recruiting Treatment Healthy Volunteers 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet, extended release Oral 25 mg Tablet, extended release Oral 50 mg Tablet, extended release Oral Tablet, film coated Oral 25 mg Tablet, film coated Oral 50 mg Tablet, film coated, extended release Oral 25 mg/1 Tablet, film coated, extended release Oral 50 mg/1 - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region CA2305802 No 2008-11-18 2018-10-15 Canada 
CA2464068 No 2007-10-16 2022-10-29 Canada CA2503570 No 2023-11-04 2011-04-19 Canada USRE44872 No 2014-04-29 2023-12-18 US 
US7750029 No 2010-07-06 2023-12-18 US US6346532 No 2002-02-12 2018-10-15 US US8835474 No 2014-09-16 2023-11-04 US US6562375 No 2003-05-13 2020-08-01 US US7982049 No 2011-07-19 2023-11-04 US US7342117 No 2008-03-11 2023-11-04 US US8772315 No 2014-07-08 2028-10-30 US
Properties
- State
- Solid
- Experimental Properties
Property Value Source water solubility Insoluble FDA label - Predicted Properties
Property Value Source Water Solubility 0.00412 mg/mL ALOGPS logP 2.2 ALOGPS logP 2.89 ChemAxon logS -5 ALOGPS pKa (Strongest Acidic) 13.84 ChemAxon pKa (Strongest Basic) 9.62 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 5 ChemAxon Hydrogen Donor Count 4 ChemAxon Polar Surface Area 100.27 Å2 ChemAxon Rotatable Bond Count 9 ChemAxon Refractivity 113.23 m3·mol-1 ChemAxon Polarizability 44.2 Å3 ChemAxon Number of Rings 3 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9398 Blood Brain Barrier + 0.8115 Caco-2 permeable - 0.6462 P-glycoprotein substrate Substrate 0.5567 P-glycoprotein inhibitor I Non-inhibitor 0.8492 P-glycoprotein inhibitor II Non-inhibitor 0.8487 Renal organic cation transporter Non-inhibitor 0.7223 CYP450 2C9 substrate Non-substrate 0.7656 CYP450 2D6 substrate Non-substrate 0.7786 CYP450 3A4 substrate Non-substrate 0.641 CYP450 1A2 substrate Non-inhibitor 0.5904 CYP450 2C9 inhibitor Inhibitor 0.6156 CYP450 2D6 inhibitor Non-inhibitor 0.8873 CYP450 2C19 inhibitor Non-inhibitor 0.574 CYP450 3A4 inhibitor Inhibitor 0.5223 CYP450 inhibitory promiscuity High CYP Inhibitory Promiscuity 0.5711 Ames test Non AMES toxic 0.6422 Carcinogenicity Non-carcinogens 0.8972 Biodegradation Not ready biodegradable 0.5977 Rat acute toxicity 2.4527 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9094 hERG inhibition (predictor II) Inhibitor 0.567
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-004j-0429000000-a1fa6e47b60253c53578
Targets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Accelerate your drug discovery research with our ADMET & drug target dataset
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Agonist
- General Function
- Protein homodimerization activity
- Specific Function
- Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
- Gene Name
- ADRB3
- Uniprot ID
- P13945
- Uniprot Name
- Beta-3 adrenergic receptor
- Molecular Weight
- 43518.615 Da
References
- Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899]
Enzymes
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Vitamin d3 25-hydroxylase activity
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
- Gene Name
- CYP3A4
- Uniprot ID
- P08684
- Uniprot Name
- Cytochrome P450 3A4
- Molecular Weight
- 57342.67 Da
References
- Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188]
- Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Steroid hydroxylase activity
- Specific Function
- Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
- Gene Name
- CYP2D6
- Uniprot ID
- P10635
- Uniprot Name
- Cytochrome P450 2D6
- Molecular Weight
- 55768.94 Da
References
- Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188]
- Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825]
- FDA Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers [Link]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Identical protein binding
- Specific Function
- Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
- Gene Name
- BCHE
- Uniprot ID
- P06276
- Uniprot Name
- Cholinesterase
- Molecular Weight
- 68417.575 Da
References
- Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825]
Carriers
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Toxic substance binding
- Specific Function
- Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
- Gene Name
- ALB
- Uniprot ID
- P02768
- Uniprot Name
- Serum albumin
- Molecular Weight
- 69365.94 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- Actions
- Substrate
- General Function
- Not Available
- Specific Function
- Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
- Gene Name
- ORM1
- Uniprot ID
- P02763
- Uniprot Name
- Alpha-1-acid glycoprotein 1
- Molecular Weight
- 23511.38 Da
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- Curator comments
- Mirabegron inhibited P-gp-mediated drug transport at high concentrations, according to the FDA Label.
- General Function
- Xenobiotic-transporting atpase activity
- Specific Function
- Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
- Gene Name
- ABCB1
- Uniprot ID
- P08183
- Uniprot Name
- Multidrug resistance protein 1
- Molecular Weight
- 141477.255 Da
References
- Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Sodium-independent organic anion transmembrane transporter activity
- Specific Function
- Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibit...
- Gene Name
- SLCO1A2
- Uniprot ID
- P46721
- Uniprot Name
- Solute carrier organic anion transporter family member 1A2
- Molecular Weight
- 74144.105 Da
References
- Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393]
Drug created on May 31, 2013 05:44 / Updated on March 04, 2021 11:02